While the IndiTreat® technology is suitable for multiple solid tumor types, our current portfolio focuses on stage IV (metastatic) colorectal cancer patients. We offer testing for first, third- and further-line treatments. To read more about IndiTreat® in general, please go here. For more information about solutions for specific lines of treatment, please see below.
Newly diagnosed patients with metastatic CRC (mCRC, synchronous metastases) or previously treated localized disease with new onset of metastases (metachronous metastases) and an indication for first-line systemic therapy are eligible for functional chemosensitivity testing using the IndiTreat® CRC Start panel.
Third-line and further-line patients
Patients with metastatic colorectal cancer (mCRC) showing tumor progression after at least two previous lines of systemic therapy are eligible for functional chemosensitivity testing using both IndiTreat® CRC Extend and IndiTreat® CRC Explore.